These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3415212)

  • 1. Activities of five new fluoroquinolones against Pseudomonas pseudomallei.
    Winton MD; Everett ED; Dolan SA
    Antimicrob Agents Chemother; 1988 Jun; 32(6):928-9. PubMed ID: 3415212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
    Smith SM
    Antimicrob Agents Chemother; 1986 Feb; 29(2):325-6. PubMed ID: 2940966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent.
    Neu HC; Labthavikul P
    Diagn Microbiol Infect Dis; 1985 Nov; 3(6):469-78. PubMed ID: 4064609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.
    Barry AL; Jones RN
    Eur J Clin Microbiol; 1987 Apr; 6(2):179-82. PubMed ID: 3474145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria.
    Fuchs PC; Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
    Diagn Microbiol Infect Dis; 1987 Mar; 6(3):185-92. PubMed ID: 3471371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
    Delmee M; Avesani V
    Antimicrob Agents Chemother; 1986 Feb; 29(2):374-5. PubMed ID: 2940968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of amifloxacin (WIN 49,375) compared with those of ciprofloxacin and ofloxacin.
    Digranes A
    Acta Pathol Microbiol Immunol Scand B; 1987 Feb; 95(1):29-32. PubMed ID: 3105246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of A-56619 and A-56620, two new quinolones.
    Barry AL; Thornsberry C; Jones RN
    Antimicrob Agents Chemother; 1986 Jan; 29(1):40-3. PubMed ID: 2942099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare.
    Fenlon CH; Cynamon MH
    Antimicrob Agents Chemother; 1986 Mar; 29(3):386-8. PubMed ID: 2940969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro comparison of amifloxacin and six other antibiotics against aminoglycoside-resistant Pseudomonas aeruginosa.
    Thompson KD; O'Keefe JP; Tatarowicz WA
    Antimicrob Agents Chemother; 1984 Aug; 26(2):275-6. PubMed ID: 6435518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
    Floyd-Reising SA; Kelley SG; Hindler JA; Young LS
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):301-6. PubMed ID: 3472704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P
    Infection; 1986; 14(3):142-4. PubMed ID: 2942489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
    Berlin OG; Young LS; Bruckner DA
    J Antimicrob Chemother; 1987 May; 19(5):611-5. PubMed ID: 3112095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of strains of Pseudomonas pseudomallei isolated in Thailand and Hong Kong to some newer beta-lactam antibiotics and quinolone derivatives.
    Chau PY; Ng WS; Leung YK; Lolekha S
    J Infect Dis; 1986 Jan; 153(1):167-70. PubMed ID: 2934486
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    Davies S; Sparham PD; Spencer RC
    J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Edlund C; Nord CE
    Scand J Infect Dis; 1986; 18(2):149-51. PubMed ID: 2939556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amifloxacin activity against well-defined gentamicin-resistant, gram-negative bacteria.
    John JF; Twitty JA
    Antimicrob Agents Chemother; 1984 Nov; 26(5):781-4. PubMed ID: 6440481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.